Skip to main content

Advertisement

Table 3 Characteristics of patients with FCHL included in the longitudinal study before and after treatment for their dyslipidemia

From: Vitamin D concentrations in familial combined hyperlipidemia: effects of lipid lowering treatment

  Off- treatment With treatment P
25(OH)D (nmol/L) 51.0 ± 31.3 58.9 ± 24.6 0.022
BMI (Kg/m2) 26.6 ± 2.6 26.6 ±2.6 0.778
Waist (cm) 92.7 ± 9.2 93.1 ± 8.8 0.518
HOMA 2.0 ± 1.1 2.2 ± 1.4 0.535
Total cholesterol (mmol/L) 7.4 (5.1-16.1) 5.1 (3.8-8.9) 0.000
Triglycerides (mmol/L) 2.8 (1.2-10.7) 1.9 (0.8-3.8) 0.000
LDL-c (mmol/L) 4.3 (1.4-7.8) 3.0 (2.0-5.8) 0.007
HDL-c (mmol/L) 1.2 ± 0.4 1.3 ± 0.3 0.000
VLDL-c (mmol/L) 1.3 (0.6-8.6) 0.9 (0.4-3.3) 0.000
NEFA (mmol/L) 0.6 (0.3-1.6) 0.6 (0.3-1.4) 0.313
ApoB (g/L) 1.4 ± 0.3 1.0 ± 0.2 0.000
LDLsize (nm) 25.3 (23.2-26.2) 25.7 (24.8-26.5) 0.058
CRP (mg/L) 2.0 (0.1-21.1) 1.3 (0.3-12.2) 0.823
  1. P values according to paired T-test and Wilcoxon test.
  2. FCHL: Familial combined hyperlipidemia, 25(OH)D: 25-hydroxyvitamin D, BMI: body mass index, HOMA: homeostasis model assessment, LDL-c: low-density lipoprotein cholesterol, HDL-c: high-density lipoprotein cholesterol, VLDL-c: very low-density lipoprotein cholesterol, LDL: low-density lipoprotein, NEFA: non-esterified fatty acids, ApoB: apolipoprotein B, CRP: C-reactive protein.